Regulatory incentives for rare disease treatments, including market exclusivity and development subsidies, are spurring pharmaceutical innovation across the US, Europe, Japan, and Australia, with multiple companies advancing therapies for conditions affecting limited patient populations.
Daily aspirin use does not prevent bowel cancer in the general population within 5-15 years and carries immediate bleeding risks, according to a new Cochrane review. However, long-term low-dose aspirin is associated with lower colorectal cancer risk in IBD patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07411079 |
Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for Intracerebral Hemorrhage |
RECRUITING | |
| NCT07205523 |
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) |
RECRUITING | |
| NCT07083583 |
Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders |
RECRUITING | |
| NCT02822599 |
Human Fibrinogen Concentrate in Pediatric Cardiac Surgery |
COMPLETED | PHASE4 |
